Announcing Synex's Series A
We're excited to announce that we've raised $21.8M in our Series A financing from both returning and new investors to accelerate toward a vision of predictive medicine.
Our vision is to enable a future where predictive medicine becomes the norm, leaving reactive healthcare in the past. Today, we believe there is a fundamental technology gap in which no product can truly monitor human health and well-being. To that end, we are building the next generation of health monitoring technology capable of providing real-time and accurate metabolic data without any pricks or needles. Our approach is based on novel techniques we’ve developed in magnetic resonance spectroscopy (MRS) that allow us to directly measure blood metabolites like glucose and lactate in highly miniaturized form-factors.
We are excited to announce that we’ve raised $21.8M in an oversubscribed Series A to accelerate toward this vision.
We’re proud to continue working with returning investors such as Accomplice, Radical Ventures, Naval Ravikant and others, as well as welcome new investors such as Khosla Ventures, Fundomo, and Aravind Srinivas.
As the first step in realizing this vision, we are developing the world’s first non-invasive glucose monitor to replace finger pricking in diabetes.
Roughly 10% of the global population suffers from diabetes, with the vast majority of people having to endure painful daily finger pricks. These new funds will help accelerate our productization and clinical validation efforts toward finally addressing this underserved population.
The technology we’re building is not just limited to glucose. With the versatility of MRS, we’re capable of measuring many other metabolites such as lactate, triglycerides and amino acids. We believe that starting with glucose allows us to address a critical unmet need, providing millions of people with a non-invasive way to monitor their blood sugar levels. By starting with glucose, we are laying the foundation for future measurements that will expand into broader metabolic monitoring, ultimately empowering people to take control of their overall health.
We’re grateful to have a group of such supportive investors behind us as we work toward this future.
“I have looked at MR glucose measurement closely enough to say with confidence it is an area that, compared to many other techniques, is relatively underexplored and deserving of further effort and investment to expand the investigation.”
Dr. John L. Smith, Former Chief Scientific Officer for Johnson & Johnson’s LifeScan division and author of The Pursuit of Noninvasive Glucose
“To be able to achieve a direct, non-invasive measurement of glucose and other metabolites is groundbreaking and helps realize the potential of predictive medicine. Synex’s vision for the future is captivating and we’re proud to support their important work.”
Alex Morgan, Khosla Ventures
This journey is a challenging one, requiring novel advancements in radiofrequency engineering, digital electronics, magnetostatics, materials science, magnetic resonance physics and machine learning. We’ve made some remarkable breakthroughs that we’re eager to share with the world and are looking for more exceptional and driven people to join us in this mission.
If our vision of the future resonates with you and you’re excited to work on challenging problems at the limits of applied physics, engineering, medicine and machine learning, we’d love to hear from you. We’re actively growing across multiple disciplines and are eager to connect with passionate people who share our ambition.
For more information and career opportunities please visit synexmedical.com or reach out at info@synexmedical.com
🥳🥳🥳